References: Hair growth and hair loss
Vopr Onkol. 2001;47(3):298-302.
[Xeloda (capecetabine) in the treatment of disseminated breast cancer after failure with anthracyclines and taxanes]
[Article in Russian]
Semiglazova TIu, Gershanovich ML.
N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
Xeloda (capecetabine) has been tested for efficacy and toxicity in treating disseminated breast cancer after the potential of anthracycline (group 1) chemotherapy, anthracyclines plus taxanes (group 2) was exhausted. The patients included into the study (54) were divided into groups 1 (33) and 2 (21). Apparent response was in 24 and 21%, respectively. The drug may be used both in out-patients and those refractory to anthracycline chemotherapy and anthracyclines plus taxanes due to moderate toxicity, slight myelodepression and absence of alopecia which seldom makes treatment useless.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11544827&dopt=Abstract
vet.uu.nl
Signs of oestrus, including vulvar swelling and alopecia are frequently seen in ovariectomized ferrets. Between 1997 and 1999, 25 ovariectomized ferrets presented with symptoms of vulvar swelling and symmetric alopecia at the University Clinic of Companion Animals. In 18 of these animals, ovarian remnants were found. To prevent failure to remove all ovarian tissue in the ferret, thorough identification of the ovaries, which are surrounded by large fat deposits, is necessary. The incision should be long enough to allow good visualization of the surgical field.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11544927&dopt=Abstract
Ann Dermatol Venereol. 1999 Feb;126(2):142-6.
[Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon-alpha]
[Article in French]
Bedane C, Le Brun V, Boulinguez S, Berdah JF, Bouyssou ML, Delpuget N, Bernard P, Tubiana-Mathieu N, Bonnetblanc JM.
Service de dermatologie, CHU, Hopital Dupuytren, Limoges.
BACKGROUND: The use of high-dose interferon alpha as adjuvant therapy has been shown for the first time to improve recurrence-free and overall survival in stage II malignant melanoma. The aim of our work was to evaluate the toxicity of this therapeutic scheme during a 1-year period in 13 patients with malignant melanoma. PATIENTS AND METHODS: Thirteen patients, mean age 56 years, with stage II melanoma were included. Interferon alpha was administered at the dose of 20 MU per m2 body surface area five days per week for four weeks during the induction phase and at the dose of 10 MU subcutaneously three times a week for 48 weeks in the maintenance phase. Patients underwent clinical assessment daily and had blood tests twice a week during the induction phase. Weekly blood tests and monthly examinations were then performed during the maintenance phase. Clinical and biological toxicity was evaluated in accordance with the WHO scores. Grade 3 toxicity led to a 30 p. 100 dose reduction and treatment was interrupted in case of grade 4 toxicity. RESULTS: A flu-like syndrome (grade 1-2) and digestive disorders, nausea, anorexia related to dysgeusia or dry mouth were observed in most of the patients during the induction phase and persisted in 30% of the patients during the maintenance phase. Six patients developed a state of depression (grade 2-3) which persisted during the maintenance phase, inciting us to prescribe an antidepressor regimen for all our patients. One patient developed major reversible alopecia at dose reduction. Nine patients had grade 1 or grade 2 neutropenia and four had grade 3 neutropenia. Seven patients developed grade 1-2 thrombocytopenia, six had elevated transaminase levels (grade 1-2) and two moderately elevated CPK. CONCLUSION: At the end of the induction phase of interferon alpha therapy in 13 patients with malignant melanoma, 8/13 had received 100 p. 100 of the theoretical dose and 11/13 had received 80 p. 100. At the end of the treatment protocol, 5/10 patients had received 100 p. 100 of the theoretical dose and 8/10 more than 80 p. 100. The proposed protocol appears to be feasible without major risk. Rigorous clinical and biological surveillance is mandatory.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10352829&dopt=Abstract
Natural Herbal Supplements ||
Hair Million herbal formula for hair loss and hair growth ||
Hair growth research references ||
Online Pharmacy : discount prescription medication ||